Loading...
This is another report from the discontinued arm of the WHI's hormone therapy trial (Journal Watch Women's Health Aug 7 2002). In this arm of the trial, 16,608 women were randomly assigned to receive either placebo or conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day).
This arm was discontinued in part because HT recipients showed an increased risk for stroke. Now, researchers provide an in-depth analysis of the types of stroke seen in these patients, as well as the associations between stroke incidence and biomarkers for inflammation and thrombosis and risk factors such as smoking, hypertension, obesity, and insulin resistance.
During a mean follow-up of 5.6 years, there were 151 strokes in the HT group (1.8%) …